Comparison of in vivo activity of fluconazole with that of amphotericin B against Candida tropicalis, Candida glabrata, and Candida krusei

M. A. Fisher, S. H. Shen, J. Haddad, W. F. Tarry

    Research output: Contribution to journalArticle

    67 Citations (Scopus)

    Abstract

    Fluconazole (UK-49,858) is a new oral bis-triazole antifungal agent with demonstrated activity against Candida albicans. Because of the increasing importance of infections due to other species of Candida, we studied the efficacy of fluconazole in a rat model of established systemic candidiasis, using clinical isolates of C. tropicalis, C. glabrata, and C. krusei. In normal rats, oral fluconazole at both 20 and 80 mg/kg per day for 7 days reduced both kidney and liver titers of C. tropicalis and C. glabrata compared with those in control animals and was only slightly inferior to amphotericin B. Both fluconazole and amphotericin B were ineffective in reducing kidney titers of C. krusei, but amphotericin B was more effective than fluconazole in reducing liver titers. Fluconazole showed no increased efficacy at the higher dose of 80 mg/kg per day compared with 20 mg/kg per day in any experiment. These results suggest that oral fluconazole may be useful in the treatment of established disseminated candidiasis caused by species other than C. albicans. Further in vivo studies are needed, however, to define minimum effective doses and length of therapy and to test additional Candida isolates.

    Original languageEnglish (US)
    Pages (from-to)1443-1446
    Number of pages4
    JournalAntimicrobial Agents and Chemotherapy
    Volume33
    Issue number9
    StatePublished - 1989

    Fingerprint

    Candida tropicalis
    Candida glabrata
    Fluconazole
    Amphotericin B
    Candida
    Candida albicans
    Kidney
    Triazoles
    Candidiasis
    Antifungal Agents
    Liver
    Infection

    ASJC Scopus subject areas

    • Pharmacology (medical)

    Cite this

    Comparison of in vivo activity of fluconazole with that of amphotericin B against Candida tropicalis, Candida glabrata, and Candida krusei. / Fisher, M. A.; Shen, S. H.; Haddad, J.; Tarry, W. F.

    In: Antimicrobial Agents and Chemotherapy, Vol. 33, No. 9, 1989, p. 1443-1446.

    Research output: Contribution to journalArticle

    @article{513e7fbcfad944248587902b69d0ee0c,
    title = "Comparison of in vivo activity of fluconazole with that of amphotericin B against Candida tropicalis, Candida glabrata, and Candida krusei",
    abstract = "Fluconazole (UK-49,858) is a new oral bis-triazole antifungal agent with demonstrated activity against Candida albicans. Because of the increasing importance of infections due to other species of Candida, we studied the efficacy of fluconazole in a rat model of established systemic candidiasis, using clinical isolates of C. tropicalis, C. glabrata, and C. krusei. In normal rats, oral fluconazole at both 20 and 80 mg/kg per day for 7 days reduced both kidney and liver titers of C. tropicalis and C. glabrata compared with those in control animals and was only slightly inferior to amphotericin B. Both fluconazole and amphotericin B were ineffective in reducing kidney titers of C. krusei, but amphotericin B was more effective than fluconazole in reducing liver titers. Fluconazole showed no increased efficacy at the higher dose of 80 mg/kg per day compared with 20 mg/kg per day in any experiment. These results suggest that oral fluconazole may be useful in the treatment of established disseminated candidiasis caused by species other than C. albicans. Further in vivo studies are needed, however, to define minimum effective doses and length of therapy and to test additional Candida isolates.",
    author = "Fisher, {M. A.} and Shen, {S. H.} and J. Haddad and Tarry, {W. F.}",
    year = "1989",
    language = "English (US)",
    volume = "33",
    pages = "1443--1446",
    journal = "Antimicrobial Agents and Chemotherapy",
    issn = "0066-4804",
    publisher = "American Society for Microbiology",
    number = "9",

    }

    TY - JOUR

    T1 - Comparison of in vivo activity of fluconazole with that of amphotericin B against Candida tropicalis, Candida glabrata, and Candida krusei

    AU - Fisher, M. A.

    AU - Shen, S. H.

    AU - Haddad, J.

    AU - Tarry, W. F.

    PY - 1989

    Y1 - 1989

    N2 - Fluconazole (UK-49,858) is a new oral bis-triazole antifungal agent with demonstrated activity against Candida albicans. Because of the increasing importance of infections due to other species of Candida, we studied the efficacy of fluconazole in a rat model of established systemic candidiasis, using clinical isolates of C. tropicalis, C. glabrata, and C. krusei. In normal rats, oral fluconazole at both 20 and 80 mg/kg per day for 7 days reduced both kidney and liver titers of C. tropicalis and C. glabrata compared with those in control animals and was only slightly inferior to amphotericin B. Both fluconazole and amphotericin B were ineffective in reducing kidney titers of C. krusei, but amphotericin B was more effective than fluconazole in reducing liver titers. Fluconazole showed no increased efficacy at the higher dose of 80 mg/kg per day compared with 20 mg/kg per day in any experiment. These results suggest that oral fluconazole may be useful in the treatment of established disseminated candidiasis caused by species other than C. albicans. Further in vivo studies are needed, however, to define minimum effective doses and length of therapy and to test additional Candida isolates.

    AB - Fluconazole (UK-49,858) is a new oral bis-triazole antifungal agent with demonstrated activity against Candida albicans. Because of the increasing importance of infections due to other species of Candida, we studied the efficacy of fluconazole in a rat model of established systemic candidiasis, using clinical isolates of C. tropicalis, C. glabrata, and C. krusei. In normal rats, oral fluconazole at both 20 and 80 mg/kg per day for 7 days reduced both kidney and liver titers of C. tropicalis and C. glabrata compared with those in control animals and was only slightly inferior to amphotericin B. Both fluconazole and amphotericin B were ineffective in reducing kidney titers of C. krusei, but amphotericin B was more effective than fluconazole in reducing liver titers. Fluconazole showed no increased efficacy at the higher dose of 80 mg/kg per day compared with 20 mg/kg per day in any experiment. These results suggest that oral fluconazole may be useful in the treatment of established disseminated candidiasis caused by species other than C. albicans. Further in vivo studies are needed, however, to define minimum effective doses and length of therapy and to test additional Candida isolates.

    UR - http://www.scopus.com/inward/record.url?scp=0024418245&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0024418245&partnerID=8YFLogxK

    M3 - Article

    C2 - 2554797

    AN - SCOPUS:0024418245

    VL - 33

    SP - 1443

    EP - 1446

    JO - Antimicrobial Agents and Chemotherapy

    JF - Antimicrobial Agents and Chemotherapy

    SN - 0066-4804

    IS - 9

    ER -